Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines

The document discusses the advancements in cell proteomic footprinting (CPF) technology, which improves the quality control of cellular and cell-derived cancer vaccines by analyzing specific proteomic patterns of cell surface proteins. CPF addresses variability in cell molecular phenotypes due to factors like isolation and cultivation, crucial for ensuring correct antigen composition in vaccines. It is particularly relevant for vaccines using cancer cells and tumor microenvironment cells, with limited examples like the antiangiogenic vaccine. CPF can identify subpopulations with distinct therapeutic properties, aiding in targeted cancer therapies. The document provides protocols for CPF implementation, contributing to its adoption in vaccine development.